Our portfolio companies

Portfolio Our portfolio companies



Taking the bold steps needed to make the small ones possible.

Oxyrane develops enzyme replacement therapies (ERT) for lysosomal storage diseases (LSDs). By applying its proprietary robust and scalable glyco-engineering yeast platform, Oxyrane produces human lysosomal enzymes containing appropriate sugar structures, which enables superior product uptake and localization resulting in greater efficacy at lower product doses.

  • Industry Biotech